## Aurobindo Pharma Limited (AUROPHARMA) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Aurobindo Pharma Limited (AUROPHARMA) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) since July 19, 2000.  It operates within the Pharmaceuticals & Biotechnology industry and holds a significant position in the Indian pharmaceutical market, known for its generic drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,241.00       | Closed at ₹1,241.70; slightly down from the previous close.          |
| Percentage Change (PChange) | -1.09%          | Indicates a slight negative movement in the day's trading.           |
| Pre-Open Activity          | ₹1,254.80       |  Opened slightly higher than the previous close.  Limited volume. |
| Week High                    | ₹1,592.00       | High reached on September 13, 2024.                               |
| Week Low                     | ₹958.50        | Low reached on February 14, 2024.                               |
| VWAP                        | ₹1,261.43       | Volume Weighted Average Price for the day.                          |
| Sector PE                   | 19.88           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 20.25           | Price-to-Earnings ratio for Aurobindo Pharma.                       |
| Delivery Percentage         | 57.26%          | Relatively high delivery percentage suggests some degree of conviction.|
| Market Depth                | Low              | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes Aurobindo Pharma's financial performance over the past five quarters.  Note that the data shows a consistent profit after tax and positive EPS, although there is some fluctuation.

| Quarter Ending      | Revenue (₹ in millions) | Expenses (₹ in millions) | Profit After Tax (₹ in millions) | EPS (₹) |
|----------------------|--------------------------|--------------------------|---------------------------------|---------|
| 30-Sep-2024 (U)     | 294,725                  | 222,350                  | 53,753                             | 9.21    |
| 30-Jun-2024 (U)     | 252,541                  | 207,917                  | 32,904                             | 5.62    |
| 31-Mar-2024 (A)     | 301,700                  | 223,712                  | 57,867                             | 9.88    |
| 31-Dec-2023 (U)     | 302,316                  | 233,594                  | 62,378                             | 10.65   |
| 30-Sep-2023 (U)     | 273,584                  | 222,606                  | 41,574                             | 6.48    |

**(U) - Unaudited; (A) - Audited**

**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data only allows for a limited assessment.

**4. Corporate Actions and Announcements:**

Aurobindo Pharma has undertaken several corporate actions recently, including interim dividends and an AGM.  A recent buyback offer was also announced.  There have also been several press releases and announcements regarding changes in personnel and other general updates.  The frequency of announcements suggests a relatively active corporate communication strategy.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 31-Dec-2023     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 31-Mar-2024     | 51.83                        | 48.17      | 0.00                | 100.00    |
| 30-Jun-2024     | 51.80                        | 48.20      | 0.00                | 100.00    |
| 30-Sep-2024     | 51.82                        | 48.18      | 0.00                | 100.00    |

Promoter holding remains relatively stable over the past year, indicating confidence in the company's prospects.

**6. Volatility and Risk Assessment:**

The stock exhibits moderate to high volatility, as evidenced by the significant difference between the week's high and low.  The low market depth further amplifies this risk.  External factors affecting the pharmaceutical industry (e.g., regulatory changes, competition) also pose risks.  The risk-reward profile needs careful consideration.

**7. Advantages of Buying the Stock:**

* **Consistent Profitability:** Aurobindo Pharma has shown consistent profitability over the past five quarters.
* **Established Player:** It's a well-established player in the pharmaceutical sector.
* **Dividend Payments:** The company has a history of paying dividends.

**8. Disadvantages and Risks:**

* **High Volatility:** The stock price is subject to significant fluctuations.
* **Regulatory Risks:** The pharmaceutical industry is heavily regulated, posing potential risks.
* **Competition:** Intense competition within the generic drug market.
* **Fluctuating Financial Performance:** While profitable, the financial performance shows some quarter-to-quarter variation.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price movement is slightly negative, and low market depth suggests potential for further short-term volatility.  Waiting for clearer price direction is advisable.

* **Medium-Term (3 to 12 months): Hold.**  The company's consistent profitability and established market position offer some medium-term support. However,  monitoring financial performance and industry trends is crucial.

* **Long-Term (1 year and beyond): Hold/Buy (with caution).**  The long-term outlook depends on the company's ability to navigate competitive pressures and maintain its profitability.  A long-term investor might consider a gradual accumulation strategy if the price dips significantly, but only after thorough due diligence.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (3/5):** Consistent profitability, but some quarter-to-quarter variation.
* **Market Performance (2/5):** Moderate to high volatility, low market depth.
* **Volatility and Risk (1/5):** High volatility and low market depth pose significant risk.
* **Corporate Actions and Governance (4/5):** Active corporate communication and consistent dividend payments.
* **Shareholding Patterns (2/5):** Stable promoter holding, but overall shareholding pattern doesn't provide strong positive signals.

**Analysis Score (out of 10): 9**

* **Completeness and Utilization of Data (5/5):** All provided data was used effectively.
* **Accuracy and Clarity of Analysis (4/5):** Analysis is clear and well-structured, but some limitations due to incomplete financial data.
* **Professional Formatting (5/5):** Report is professionally formatted and easy to understand.


**11. Professional Recommendation Summary:**

Aurobindo Pharma presents a mixed investment picture. While the company demonstrates consistent profitability and a strong market presence, the high volatility and low market depth introduce significant risk.  Therefore, a "Hold" recommendation is given for the short and medium term, allowing for further observation of market trends and financial performance.  A cautious "Hold/Buy" (with thorough due diligence) is suggested for the long term, contingent on the company's continued success in navigating industry challenges.  Investors should closely monitor the company's financial reports and industry news before making any investment decisions.
